Effect of prostate size on pathological outcome and biochemical recurrence after radical prostatectomy for prostate cancer: Is it correlated with serum testosterone level?

BJU International

Volumn 106, Issue 5, 2010, Pages 633-638

  Kwon, Taekmin ^a   Jeong, In Gab ^a   You, Dalsan ^a   Park, Myung Chan ^a   Hong, Jun Hyuk ^a   Ahn, Hanjong ^a   Kim, Choung Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

prognosis; prostate cancer; size; testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE SIZE; PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL;

AGED; EPIDEMIOLOGIC METHODS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGAN SIZE; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 77955863428     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09182.x     Document Type: Article

References (30)

1. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 352 : 1977 84
2. Walz J, Chun FK, Klein EA et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 2009 181 : 601 7
3. Freedland SJ, Isaacs WB, Platz EA et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 2005 23 : 7546 54
4. Hong SK, Yu JH, Han BK et al. Association of prostate size and tumor grade in Korean men with clinically localized prostate cancer. Urology 2007 70 : 91 5
5. Schroeck FR, Sun L, Freedland SJ, Jayachandran J, Robertson CN, Moul JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 2008 11 : 371 6
6. Isom-Batz G, Bianco FJ Jr., Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005 173 : 1935 7
7. Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008 72 : 1240 5
8. Massengill JC, Sun L, Moul JW et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003 169 : 1670 5
9. Yamamoto S, Yonese J, Kawakami S et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007 52 : 696 701
10. Msezane LP, Gofrit ON, Lin S, Shalhav AL, Zagaja GP, Zorn KC. Prostate weight: an independent predictor for positive surgical margins during robotic-assisted laparoscopic radical prostatectomy. Can J Urol 2007 14 : 3697 701
11. Jeong CW, Park HK, Hong SK, Byun SS, Lee HJ, Lee SE. Comparison of prostate Volume measured by transrectal ultrasonography and MRI with the actual prostate volume measured after radical prostatectomy. Urol Int 2008 81 : 179 85
12. Piro C, Fraioli F, Sciarra F, Conti C. Circadian rhythm of plasma testosterone, cortisol and gonadotropins in normal male subjects. J Steroid Biochem 1973 4 : 321 9
13. Gleason DF. Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr 1988 15 8
14. Mettlin CJ, Murphy GP, Cunningham MP, Menck HR. The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment. Cancer 1997 80 : 1261 6
15. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001 165 : 1146 51
16. Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997 20 : 605 8
17. Song C, Ahn H, Lee MS et al. Mass screening for prostate cancer in Korea: a population based study. J Urol 2008 180 : 1949 52
18. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999 59 : 4161 4
19. Giovannucci E, Stampfer MJ, Krithivas K et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997 94 : 3320 3
20. Makridakis NM, Reichardt JK. Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression. J Urol 2004 171 : S25 8
21. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 1991 265 : 618 21
22. Zagars GK, Pollack A, von Eschenbach AC. Serum testosterone - a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 1997 49 : 327 34
23. Monda JM, Myers RP, Bostwick DG, Oesterling JE. The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. Urology 1995 46 : 62 4
24. D'Amico AV, Chen MH, Malkowicz SB et al. Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ngml or less. J Urol 2002 167 : 2025 30
25. Schatzl G, Madersbacher S, Thurridl T et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001 47 : 52 8
26. Luo J, Duggan DJ, Chen Y et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001 61 : 4683 8
27. Stamey TA, Warrington JA, Caldwell MC et al. Molecular genetic profiling of Gleason grade 45 prostate cancers compared to benign prostatic hyperplasia. J Urol 2001 166 : 2171 7
28. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology 1998 52 : 631 6
29. Foley CL, Bott SR, Thomas K, Parkinson MC, Kirby RS. A large prostate at radical retropubic prostatectomy does not adversely affect cancer control, continence or potency rates. BJU Int 2003 92 : 370 4
30. Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000 163 : 1155 60